We represented direct purchasers in a class action alleging that Pfizer delayed generic competition for its successful pain reliever Celebrex, by making misrepresentations and omitting material facts before the USPTO in order to obtain a reissue patent covering Celebrex, and that asserting to the patent prevented generic versions of Celebrex from entering the United States market. On the eve of trial, the case settled for $94 million.